XOMA/$XOMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XOMA
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Ticker
$XOMA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
13
ISIN
US98419J2069
Website
XOMA Metrics
BasicAdvanced
$302M
-
-$0.73
0.94
-
Price and volume
Market cap
$302M
Beta
0.94
52-week high
$33.31
52-week low
$18.35
Average daily volume
74K
Financial strength
Current ratio
5.541
Quick ratio
5.424
Long term debt to equity
118.513
Total debt to equity
135.24
Interest coverage (TTM)
-1.70%
Profitability
EBITDA (TTM)
-22.682
Gross margin (TTM)
90.36%
Net profit margin (TTM)
-6.66%
Operating margin (TTM)
-54.63%
Effective tax rate (TTM)
66.43%
Revenue per employee (TTM)
$3,300,000
Management effectiveness
Return on assets (TTM)
-6.78%
Return on equity (TTM)
-3.42%
Valuation
Price to revenue (TTM)
6.929
Price to book
3.56
Price to tangible book (TTM)
5.09
Price to free cash flow (TTM)
-27.603
Free cash flow yield (TTM)
-3.62%
Free cash flow per share (TTM)
-91.29%
Growth
Revenue change (TTM)
638.41%
Earnings per share change (TTM)
-81.35%
3-year revenue growth (CAGR)
1.62%
10-year revenue growth (CAGR)
9.01%
3-year earnings per share growth (CAGR)
-9.94%
10-year earnings per share growth (CAGR)
-25.40%
What the Analysts think about XOMA
Analyst ratings (Buy, Hold, Sell) for XOMA stock.
Bulls say / Bears say
XOMA's recent acquisition of over 60 early-stage programs from Twist Bioscience has significantly expanded its royalty and milestone portfolio, potentially leading to increased future revenues. (globenewswire.com)
Analysts have raised XOMA's price target to $74, maintaining a 'Buy' rating, indicating strong confidence in the company's growth prospects. (marketscreener.com)
XOMA reported a quarterly earnings per share of $0.06, surpassing estimates by $0.36, reflecting strong financial performance. (nasdaq.com)
StockNews.com downgraded XOMA to a 'Sell' rating, suggesting potential concerns about the company's future performance. (marketbeat.com)
XOMA reported a net loss of $4.0 million in Q4 2024, primarily due to $30.9 million in non-cash credit losses on purchased receivables, indicating financial challenges. (stocktitan.net)
Insider trading activity shows significant sales by major shareholders, which could indicate a lack of confidence in the company's short-term prospects. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2025.
XOMA Financial Performance
Revenues and expenses
XOMA Earnings Performance
Company profitability
XOMA News
AllArticlesVideos
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
GlobeNewsWire·4 days ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
GlobeNewsWire·2 weeks ago
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for XOMA stock?
XOMA (XOMA) has a market cap of $302M as of July 01, 2025.
What is the P/E ratio for XOMA stock?
The price to earnings (P/E) ratio for XOMA (XOMA) stock is 0 as of July 01, 2025.
Does XOMA stock pay dividends?
No, XOMA (XOMA) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next XOMA dividend payment date?
XOMA (XOMA) stock does not pay dividends to its shareholders.
What is the beta indicator for XOMA?
XOMA (XOMA) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.